Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [ 11 C]-(+)-PHNO PET with methylphenidate challenge study

Patients at clinical high-risk (CHR) for psychosis show elevations in [ 18 F]DOPA uptake, an estimate of dopamine (DA) synthesis capacity, in the striatum predictive of conversion to schizophrenia. Intrasynaptic DA levels can be inferred from imaging the change in radiotracer binding at D 2 receptors due to a pharmacological challenge. Here, we used methylphenidate, a DA reuptake inhibitor, and [ 11 C]-(+)-PHNO, to measure synaptic DA availability in CHR both in striatal and extra-striatal brain regions. Fourteen unmedicated, nonsubstance using CHR individuals and 14 matched control subjects participated in the study. Subjects underwent two [ 11 C]-(+)-PHNO scans, one at baseline and one following administration of a single oral dose (60 mg) of methylphenidate. [ 11 C]-(+)-PHNO BP ND , the binding potential relative to the nondisplaceable compartment, was derived using the simplified reference tissue model with cerebellum as reference tissue. The percent change in BP ND between scans, ΔBP ND , was computed as an index of synaptic DA availability, and group comparisons were performed with a linear mixed model. An overall trend was found for greater synaptic DA availability (∆BP ND ) in CHR than controls ( p = 0.06). This was driven entirely by ∆BP ND in ventral striatum (−34 ± 14% in CHR, −20 ± 12% in HC; p = 0.023). There were no significant group differences in any other brain region. There were no significant differences in DA transmission in any striatal region between converters and nonconverters, although this finding is limited by the small sample size ( N = 2). There was a strong and negative correlation between ΔBP ND in VST and severity of negative symptoms at baseline in the CHR group ( r = −0.66, p < 0.01). We show abnormally increased DA availability in the VST in CHR and an inverse relationship with negative symptoms. Our results suggest a potential early role for mesolimbic dopamine overactivity in CHR. Longitudinal studies are needed to ascertain the significance of the differential topography observed here with the [ 18 F]DOPA literature.